Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BIIB stock price vs BIO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BIO's multiple
Needs BIO P/E.
Implied fair value · at BIIB's multiple
Needs BIIB P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOGEN INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIO-RAD LABORATORIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
BIIB vs PFE
JOHNSON & JOHNSON
BIIB vs JNJ
AMGEN INC
BIIB vs AMGN
ELI LILLY & Co
BIIB vs LLY
Natera, Inc.
BIIB vs NTRA
ILLUMINA, INC.
BIIB vs ILMN
DANAHER CORP /DE/
BIIB vs DHR
AGILENT TECHNOLOGIES, INC.
BIIB vs A
BIO-TECHNE Corp
BIIB vs TECH
BRUKER CORP
BIIB vs BRKR
Azenta, Inc.
BIIB vs AZTA
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BIIB can sustain its higher ROIC and operating margin while closing the gap to the upper end of its valuation ranges, then hold or selectively accumulate; otherwise, reduce exposure because the current price embeds a valuation premium despite a model-implied downside of -49.4%.
BIIB trades at 23.1x P/E versus BIO at 11.7x, yet the valuation output implies a price of $102.73 for BIIB, or -49.4% downside from $202.95. The stock also sits above the DCF range and above the upper end of BIO-implied range, suggesting the current price is rich relative to both intrinsic and BIO benchmarks.
Supporting Metrics
